Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axsome Thera
(NQ:
AXSM
)
87.91
-0.25 (-0.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axsome Thera
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
May 11, 2024
Three most undervalued biotech stocks to buy now will take off in the coming years and bring back continuous, hefty returns.
Via
InvestorPlace
Prediction: These 2 Growth Stocks Could Triple By 2030
May 11, 2024
These companies have a habit of silencing the bears.
Via
The Motley Fool
Axsome Therapeutics to Present at Upcoming Investor Conferences
May 08, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
May 06, 2024
AXSM earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
AXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 06, 2024
AXSM stock results show that Axsome Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
April 29, 2024
Via
Benzinga
Analyst Ratings For Axsome Therapeutics
April 10, 2024
Via
Benzinga
2 Under-the-Radar Growth Stocks to Consider
April 10, 2024
Don't ignore these innovative companies.
Via
The Motley Fool
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 06, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
May 01, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
What Analysts Are Saying About Axsome Therapeutics Stock
March 19, 2024
Via
Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
February 27, 2024
Via
Benzinga
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
April 30, 2024
Here are our top three choices for biotech stocks with blockbuster drug pipelines that could pay off massively in the future.
Via
InvestorPlace
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
April 16, 2024
Stocks that work for billionaires aren't necessarily appropriate for every investor.
Via
The Motley Fool
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 12, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
April 10, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
April 01, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
March 27, 2024
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.
Via
InvestorPlace
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
March 26, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
March 25, 2024
Unlock insights from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. AXS-12 demonstrated significant reductions in cataplexy attacks, improved daytime wakefulness, and...
Via
Benzinga
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
March 23, 2024
The price could be right for these three biopharma stocks.
Via
The Motley Fool
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
March 19, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.